IN2014CN04734A - - Google Patents

Info

Publication number
IN2014CN04734A
IN2014CN04734A IN4734CHN2014A IN2014CN04734A IN 2014CN04734 A IN2014CN04734 A IN 2014CN04734A IN 4734CHN2014 A IN4734CHN2014 A IN 4734CHN2014A IN 2014CN04734 A IN2014CN04734 A IN 2014CN04734A
Authority
IN
India
Prior art keywords
cells
vectors
compositions
biologically active
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Kevin Polach
Jason Fewell
Khursheed Anwer
Lestlie S Wilkinson
Original Assignee
Egen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egen Inc filed Critical Egen Inc
Publication of IN2014CN04734A publication Critical patent/IN2014CN04734A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/85Fusion polypeptide containing an RNA binding domain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • C12N2330/51Specially adapted vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/48Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN4734CHN2014 2011-12-23 2012-12-24 IN2014CN04734A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579815P 2011-12-23 2011-12-23
PCT/US2012/071576 WO2013096958A1 (fr) 2011-12-23 2012-12-24 Compositions et procédés pour l'administration d'arn biologiquement actifs

Publications (1)

Publication Number Publication Date
IN2014CN04734A true IN2014CN04734A (fr) 2015-09-18

Family

ID=48654938

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4734CHN2014 IN2014CN04734A (fr) 2011-12-23 2012-12-24

Country Status (10)

Country Link
US (1) US20130164845A1 (fr)
EP (1) EP2794879A4 (fr)
JP (1) JP2015507474A (fr)
KR (1) KR20140123054A (fr)
CN (1) CN104169419A (fr)
AU (1) AU2012358181A1 (fr)
CA (1) CA2860228A1 (fr)
HK (1) HK1203548A1 (fr)
IN (1) IN2014CN04734A (fr)
WO (1) WO2013096958A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11639371B2 (en) * 2016-02-17 2023-05-02 The Chinese University Of Hong Kong Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
US11352625B2 (en) 2017-01-12 2022-06-07 Duke University Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease
EP3645012A4 (fr) * 2017-06-28 2021-06-30 University Of South Florida Gène ube3a modifié pour une approche de thérapie génique du syndrome d'angelman
EP3908328A1 (fr) * 2019-01-10 2021-11-17 BioNTech RNA Pharmaceuticals GmbH Administration localisée de molécules d'arn pour la thérapie
EP3806895B1 (fr) * 2019-02-15 2023-06-21 Atreca, Inc. Anticorps liant un tissu tumoral et leurs utilisations diagnostiques et thérapeutiques
CN114807194B (zh) * 2020-08-31 2023-05-12 南京工业大学 一种提高梭菌中蛋白表达效率的方法
EP4337174A4 (fr) * 2021-05-13 2025-10-29 Technion Res & Dev Foundation Méthodes et compositions pour le traitement d'infections virales
JP2025510135A (ja) * 2022-03-24 2025-04-14 セル・アンド・ブレイン・カンパニー・リミテッド 新規組換えベクターおよびその用途
EP4303305A1 (fr) * 2022-07-07 2024-01-10 Kutzner, Christoph Polypeptides de fusion pour la pénétration cellulaire et le ciblage cellulaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
EP1540004A4 (fr) * 2002-07-31 2007-10-03 Nucleonics Inc Structures et constructions d'arn a double brin, et leurs procedes de production et d'utilisation
MXPA05003287A (es) * 2002-09-28 2005-07-05 Massachusetts Inst Technology Influenza terapeutica.
US20090004668A1 (en) * 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
EP2406379A4 (fr) * 2009-03-13 2012-09-26 Egen Inc Compositions et procédés pour l'administration d'arn biologiquement actifs
DK2539451T3 (da) * 2010-02-24 2016-04-04 Arrowhead Res Corp Sammensætninger til målrettet tilførsel af siRNA

Also Published As

Publication number Publication date
EP2794879A4 (fr) 2015-10-14
CA2860228A1 (fr) 2013-06-27
CN104169419A (zh) 2014-11-26
AU2012358181A1 (en) 2014-07-10
AU2012358181A8 (en) 2015-06-18
JP2015507474A (ja) 2015-03-12
US20130164845A1 (en) 2013-06-27
WO2013096958A8 (fr) 2014-07-24
EP2794879A1 (fr) 2014-10-29
WO2013096958A1 (fr) 2013-06-27
KR20140123054A (ko) 2014-10-21
HK1203548A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
IN2014CN04734A (fr)
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
EP3839050A3 (fr) Ciblage génique non disruptif
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
WO2012075040A3 (fr) Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
MX2023006109A (es) Ligandos de direccion.
PH12013500741A1 (en) Peptide-based in vivo sirna delivery system
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
WO2012135805A3 (fr) Administration et formulation d'acides nucléiques génétiquement modifiés
MX357803B (es) Moléculas de ácido nucleico artificiales.
CA2851316C (fr) Genes et proteines pour la synthese d'alcanoyl-coa
MX358706B (es) Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
CA2863964C (fr) Procede compartimente d'administration d'acide nucleique et ses compositions et utilisations
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
WO2012019168A3 (fr) Acides nucléiques modifiés et leurs procédés d'utilisation
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
WO2011038160A3 (fr) Compositions et procédés pour réduire au silence des gènes exprimés dans le cancer
PH12012502272A1 (en) Biological materials related to her3
WO2012024396A3 (fr) Compositions et méthodes permettant d'administrer des molécules d'acide nucléique et de traiter un cancer
WO2021113851A3 (fr) Véhicule d'amarrage de peptides pour l'administration ciblée d'acides nucléiques
WO2011131360A8 (fr) Procédé de détermination du potentiel métastatique d'une tumeur
MX2015005867A (es) Moleculas de transporte especificas de proteoglicano c4s.
WO2011054939A3 (fr) Compositions et procédés pour inhiber l'expression de gènes kif10
WO2014006452A3 (fr) Peptides facteurs d'alcalinisation rapide pour la délivrance de molécules d'acide nucléique dans des cellules